Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
Related Posts
Wall Street has mixed feelings toward European stocks for 2025. Here are their big calls
While some banks are bearish, and expect a decline, others are forecasting high single digit gains for the Stoxx Europe 600 index.
Match appoints Zillow co-founder Spencer Rascoff as CEO
Match Group announced Zillow co-founder Spencer Rascoff as its new CEO in a release Tuesday.
Trump, Elon Musk to hold joint event as DOGE loses its leader, top staffers
Musk, the Tesla and SpaceX CEO, worked for Trump’s DOGE effort after spending over $250 million helping to get him elected.